162744-59-4

Basic information

• Product Name: 4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL
• Synonyms: 2,6-DIFLUORO-4-BROMOBENZYLALCOHOL;4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL;RARECHEM AL BD 1306;4-bromo-2,6-difluorobenzyl;4-bromo-2,6-difluoro-benzenemethanol
• CAS NO: 162744-59-4
• Molecular Formula: C₇H₅BrF₂O
• Molecular Weight: 223.01
• EINECS: 1533716-785-6
• Product Categories: Benzhydrols, Benzyl & Special Alcohols;Alcohol;Miscellaneous;Alcohols;C7 to C8;Oxygen Compounds;Pharmaceutical intermediate
• Mol File: 162744-59-4.mol

Chemical Properties

• Melting Point: 76-81 °C(lit.)
• Boiling Point: 250℃
• Flash Point: 105℃
• Appearance: /Solid
• Density: 1.744
• Vapor Pressure: 0.0118mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.21±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL(162744-59-4)
• EPA Substance Registry System: 4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL(162744-59-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 162744-59-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL is used as an intermediate in the synthesis of agrochemicals to help create effective pesticides and other agricultural products.
Used in Organic Compound Production:
4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL is used as a building block in the production of various organic compounds, playing a crucial role in the creation of a wide range of chemical products.
Used in Research and Development:
4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL is utilized in research and development laboratories for its versatile properties, enabling scientists to explore new applications and advancements in chemical synthesis and compound development.
Used in Industrial Settings:
4-BROMO-2,6-DIFLUOROBENZYL ALCOHOL is employed in industrial settings for its practical applications in the manufacturing process of various products, taking advantage of its chemical properties to improve efficiency and effectiveness.

InChI:InChI=1/C7H5BrF2O/c8-4-1-6(9)5(3-11)7(10)2-4/h1-2,11H,3H2

Upstream product

• 461-96-1 3,5-difluorobromobenzene 
• 183065-68-1 4-bromo-2,6-difluorobenzoic acid 

Downstream Products

• 870075-54-0 ((4-bromo-2,6-difluorobenzyl)oxy)(tert-butyl)dimethylsilane 
• 869361-54-6 4-bromo-2,6-difluorobenzyl methanesulfonate 
• 537033-54-8 2-(4-bromo-2,6-difluorophenyl)acetic acid 
• 537033-52-6 2-(4-bromo-2,6-difluorophenyl)acetonitrile 
• 1417736-43-6 [2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol 
• 1417736-75-4 rac-tert-butyl 3-{4-amino-5-[3,5-difluoro-4-(hydroxymethyl)phenyl]pyrrolo[2,1-f][1,2,4]triazin-7-yl}-3-hydroxypiperidine-1-carboxylate 
• 1417736-42-5 rac-1-{4-amino-5-[3,5-difluoro-4-(hydroxymethyl)phenyl]pyrrolo[2,1-f][1,2,4]triazin-7-yl}ethanol 
• 1417736-41-4 [4-(4-amino-7-isopropylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-2,6-difluorophenyl]methanol 
• 1417736-32-3 (4-{4-amino-7-[2-(aminomethyl)-1,3-thiazol-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl}-2,6-difluorophenyl)methanol 
• 1417736-31-2 1-{4-amino-5-[3 ,5-difluoro-4-(hydroxymethyl)phenyl]pyrrolo[2,1-f][1,2,4]triazin-7-yl}cyclohexanol trifluoroacetate 
• 917969-79-0 [3,5-difluoro-4-(hydroxymethyl)phenyl]boronic acid 
• 228421-83-8 3,5-difluoro-4-(hydroxymethyl)benzonitrile 
• 537013-51-7 4-bromo-2,6-difluorobenzaldehyde 
• 162744-60-7 5-bromo-2-(bromomethyl)-1,3-difluoro-benzene 

Relevant articles and documents

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

Study on the compounds containing 19F and 10B atoms in a single molecule for the application to MRI and BNCT

Magnetic resonance imaging (MRI) and boron-neutron capture therapy (BNCT) are quite attractive techniques for diagnosis and treatment of cancer, respectively. In order to progress the study on both MRI and BNCT, the novel compounds containing 19/sup

Isothiazole derivatives useful as anticancer agents

The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2and R3are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.